NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

[1]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[3]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[4]  W. Jagust,et al.  Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease , 1988, Magnetic resonance in medicine.

[5]  Desktop medicine. , 1990, Colorado medicine.

[6]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[7]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[8]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[9]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[10]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[11]  M. Bobinski,et al.  The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease , 1999, Neuroscience.

[12]  K. Blennow,et al.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.

[13]  Nick C Fox,et al.  Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images , 2001, The Lancet.

[14]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[15]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[16]  K. Blennow,et al.  Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds , 2003, Dementia and Geriatric Cognitive Disorders.

[17]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[18]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[19]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[20]  J. Schneider,et al.  Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. , 2004, Archives of neurology.

[21]  M. Weiner,et al.  Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia , 2005, Annals of neurology.

[22]  K. Blennow,et al.  Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease , 2006, Neurobiology of Aging.

[23]  K. Blennow,et al.  Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury , 2006, Neurology.

[24]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[25]  Yvette I. Sheline,et al.  Potential antecedent marker of Alzheimer disease , 2006 .

[26]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[27]  Pieter Visser,et al.  Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. , 2006 .

[28]  S. Haneuse,et al.  Pathological correlates of dementia in a longitudinal, population‐based sample of aging , 2007, Annals of neurology.

[29]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[30]  Nathan Herrmann,et al.  Clinical practice guidelines for severe Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[31]  J. Greene.  The abnormal and the pathological: Cholesterol, statins, and the threshold of disease , 2007 .

[32]  I. McKeith,et al.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.

[33]  K. Blennow,et al.  Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  P. Scheltens,et al.  The significance of medial temporal lobe atrophy , 2007, Neurology.

[35]  John Q. Trojanowski,et al.  Physical activity and cognitive health , 2007, Alzheimer's & Dementia.

[36]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[37]  Peter T Nelson,et al.  Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort: Neuritic Plaques and Neurofibrillary Tangles "Do Count" When Staging Disease Severity , 2007, Journal of neuropathology and experimental neurology.

[38]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[39]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[40]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[41]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[42]  Olga Pletnikova,et al.  Effect of infarcts on dementia in the Baltimore longitudinal study of aging , 2008, Annals of neurology.

[43]  W. Jagust,et al.  Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.

[44]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[45]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[46]  W. Markesbery,et al.  The Effect of APOE-ϵ4 on Dementia is Mediated by Alzheimer Neuropathology , 2009 .

[47]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[48]  W. Markesbery,et al.  The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. , 2009, Alzheimer disease and associated disorders.

[49]  B. Miller,et al.  Neurodegenerative Diseases Target Large-Scale Human Brain Networks , 2009, Neuron.

[50]  C. Rowe,et al.  The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies , 2009, Journal of Nuclear Medicine.

[51]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[52]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[53]  J. Morris,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[54]  Leslie H. Sobin,et al.  TNM Classification of Malignant Tumours, 7th Edition , 2009 .

[55]  H. Kuo,et al.  Diabetes and the Risk of Multi-System Aging Phenotypes: A Systematic Review and Meta-Analysis , 2009, PloS one.

[56]  D. Bennett,et al.  The neuropathology of older persons with and without dementia from community versus clinic cohorts. , 2009, Journal of Alzheimer's disease : JAD.

[57]  D. Harvey,et al.  Measuring cognitive reserve based on the decomposition of episodic memory variance. , 2010, Brain : a journal of neurology.

[58]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[59]  C. Jack,et al.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.

[60]  Keith A. Johnson,et al.  Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.

[61]  Chengjie Xiong,et al.  YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.

[62]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[63]  K. Blennow,et al.  Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease , 2010, Brain Research.

[64]  S. Leurgans,et al.  Neurodegenerative basis of age-related cognitive decline , 2010, Neurology.

[65]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[66]  L. Ferrucci,et al.  Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.

[67]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[68]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[69]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[70]  Nick C. Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup , 2011 .

[71]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[72]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[73]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[74]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[75]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[76]  Richard J. Kryscio,et al.  Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies , 2011, Acta Neuropathologica.

[77]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[78]  R. Coleman,et al.  Use of Florbetapir-PET for Imaging-Amyloid Pathology , 2011 .

[79]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[80]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[81]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[82]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[83]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[84]  C. Jack,et al.  Ecology of the aging human brain. , 2011, Archives of neurology.

[85]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[86]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[87]  F. LaFerla,et al.  Soluble Aβ promotes wild-type tau pathology in vivo , 2012, Alzheimer's & Dementia.

[88]  C. Jack,et al.  Effect of lifestyle activities on alzheimer disease biomarkers and cognition , 2012, Annals of neurology.

[89]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[90]  Daniel Rueckert,et al.  Injury markers predict time to dementia in subjects with MCI and amyloid pathology , 2012, Neurology.

[91]  Elizabeth C Mormino,et al.  Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.

[92]  Howard Aizenstein,et al.  Why we need two cutoffs for amyloid imaging: Early versus Alzheimer's-like amyloid-positivity , 2012, Alzheimer's & Dementia.

[93]  Frank M LaFerla,et al.  A novel BACE1-regulating protein with therapeutic potential , 2012, Alzheimer's & Dementia.

[94]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[95]  R. Green,et al.  The Framingham Brain Donation Program: neuropathology along the cognitive continuum. , 2012, Current Alzheimer research.

[96]  Olivier Salvado,et al.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.

[97]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[98]  R. Wilson,et al.  Relation of neuropathology to cognition in persons without cognitive impairment , 2012, Annals of neurology.

[99]  Denise C. Park,et al.  &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.

[100]  Paul Edison,et al.  A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[102]  Nick C Fox,et al.  Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.

[103]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[104]  Miranka Wirth,et al.  Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not β-Amyloid in Cognitively Normal Older Individuals , 2013, The Journal of Neuroscience.

[105]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[106]  M. Nalls,et al.  Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype , 2013, Biological Psychiatry.

[107]  Keith A. Johnson,et al.  Preclinical Alzheimer disease—the challenges ahead , 2013, Nature Reviews Neurology.

[108]  C. Rowe,et al.  Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.

[109]  Wiesje M. van der Flier,et al.  Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints , 2013, Alzheimer's & Dementia.

[110]  P. Scheltens,et al.  Impact of molecular imaging on the diagnostic process in a memory clinic , 2013, Alzheimer's & Dementia.

[111]  M. Mintun,et al.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.

[112]  Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Neurology.

[113]  Cindee M. Madison,et al.  Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. , 2013, JAMA neurology.

[114]  A. Fagan,et al.  Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Alzheimer's & Dementia.

[115]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.

[116]  C. Jack,et al.  Mild cognitive impairment due to Alzheimer disease in the community , 2013, Annals of neurology.

[117]  Christine Haberler,et al.  Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series , 2013, Acta Neuropathologica.

[118]  Leslie M. Shaw,et al.  Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium , 2013, Alzheimer's & Dementia.

[119]  C. Jack,et al.  Brain injury biomarkers are not dependent on β‐amyloid in normal elderly , 2013, Annals of neurology.

[120]  C. Jack,et al.  Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. , 2013, JAMA neurology.

[121]  A. Fagan,et al.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.

[122]  Keith A. Johnson,et al.  Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.

[123]  Stephen F. Carter,et al.  Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease , 2013, Neurology.

[124]  Vincent Doré,et al.  In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[125]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[126]  W. M. van der Flier,et al.  Preclinical AD predicts decline in memory and executive functions in subjective complaints , 2013, Neurology.

[127]  William Jagust,et al.  Vulnerable Neural Systems and the Borderland of Brain Aging and Neurodegeneration , 2013, Neuron.

[128]  A. Dale,et al.  What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus , 2014, Progress in Neurobiology.

[129]  Christos Davatzikos,et al.  Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition , 2014, Acta neuropathologica communications.

[130]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[131]  Hélène Jacqmin-Gadda,et al.  Estimating long-term multivariate progression from short-term data , 2014, Alzheimer's & Dementia.

[132]  L. Grinberg,et al.  Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.

[133]  J. Becker,et al.  Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old , 2014, Neurology.

[134]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[135]  Reisa A. Sperling,et al.  Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease , 2014, Science Translational Medicine.

[136]  Walter Kukull,et al.  Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology , 2014, Neurology.

[137]  Keith A. Johnson,et al.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. , 2014, JAMA neurology.

[138]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[139]  C. Jack,et al.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study , 2014, The Lancet Neurology.

[140]  K. Blennow,et al.  Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. , 2014, JAMA neurology.

[141]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[142]  Keith A. Johnson,et al.  Mild to moderate Alzheimer dementia with insufficient neuropathological changes , 2014, Annals of neurology.

[143]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[144]  Margaret A. Pericak-Vance,et al.  Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias , 2014, PLoS genetics.

[145]  N. Laskaris,et al.  Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[146]  Nick C Fox,et al.  A data-driven model of biomarker changes in sporadic Alzheimer's disease , 2014, Alzheimer's & Dementia.

[147]  G. Arbanas.  Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .

[148]  Charles DeCarli,et al.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.

[149]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[150]  A. Fagan,et al.  Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. , 2015, JAMA neurology.

[151]  Philip S. Insel,et al.  Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. , 2015, Brain : a journal of neurology.

[152]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[153]  Chengjie Xiong,et al.  Age and amyloid effects on human central nervous system amyloid‐beta kinetics , 2015, Annals of neurology.

[154]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[155]  K. Blennow,et al.  Amyloid biomarkers in Alzheimer's disease. , 2015, Trends in pharmacological sciences.

[156]  D. Louis Collins,et al.  The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity , 2015, Alzheimer's & Dementia.

[157]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[158]  W. M. van der Flier,et al.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. , 2015, Brain : a journal of neurology.

[159]  S. Leurgans,et al.  Mixed pathology is more likely in black than white decedents with Alzheimer dementia , 2015, Neurology.

[160]  K. Blennow,et al.  Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.

[161]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[162]  Kerstin Heurling,et al.  [18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β pathology , 2015, Alzheimer's & Dementia.

[163]  W. M. van der Flier,et al.  Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. , 2015, JAMA neurology.

[164]  Clifford R. Jack,et al.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[165]  G. Chételat,et al.  Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease , 2015, The Journal of Neuroscience.

[166]  B. Dickerson,et al.  Suspected non-AD pathology in mild cognitive impairment , 2015, Neurobiology of Aging.

[167]  Stine K. Krogsrud,et al.  Neurodevelopmental origins of lifespan changes in brain and cognition , 2016, Proceedings of the National Academy of Sciences.

[168]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[169]  Brian A. Gordon,et al.  Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. , 2016, JAMA neurology.

[170]  Keith A. Johnson,et al.  Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. , 2016, JAMA neurology.

[171]  C. Jack,et al.  LEVELS OF TAU PROTEIN IN PLASMA ARE ASSOCIATED WITH NEURODEGENERATION AND COGNITIVE FUNCTION IN A POPULATION-BASED ELDERLY COHORT , 2016, Alzheimer's & Dementia.

[172]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[173]  Yi Su,et al.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.

[174]  D. Bennett,et al.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. , 2016, Brain : a journal of neurology.

[175]  A. Fagan,et al.  Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status , 2016, Acta Neuropathologica.

[176]  Chengjie Xiong,et al.  Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease , 2016, Annals of neurology.

[177]  Eric E. Smith,et al.  Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment , 2016, Alzheimer's & Dementia.

[178]  W. Jagust,et al.  Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI , 2016, Neurology.

[179]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[180]  W. M. van der Flier,et al.  Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. , 2016, Brain : a journal of neurology.

[181]  Brian A. Gordon,et al.  NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers , 2016, Neurobiology of Aging.

[182]  Hanna Cho,et al.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.

[183]  C. Rowe,et al.  Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study , 2016, The Lancet Neurology.

[184]  Yi Su,et al.  The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. , 2016, Brain : a journal of neurology.

[185]  Christopher J. Owen,et al.  Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease , 2016 .

[186]  A. Fagan,et al.  Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study , 2016, Neurology.

[187]  O. Hansson,et al.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography , 2016, Brain : a journal of neurology.

[188]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[189]  M. Diamond,et al.  Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo , 2016, Neuron.

[190]  C. Jack,et al.  Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. , 2016, JAMA neurology.

[191]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[192]  David T. Jones,et al.  Cascading network failure across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[193]  Keith A. Johnson,et al.  Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly , 2016, Neurology.

[194]  Talakad G. Lohith,et al.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.

[195]  F. Schmitt,et al.  Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology , 2016, Alzheimer's & Dementia.

[196]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[197]  W. M. van der Flier,et al.  Diagnostic impact of [18F]flutemetamol PET in early-onset dementia , 2017, Alzheimer's Research & Therapy.

[198]  K. Blennow,et al.  Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders , 2016, Alzheimer's & dementia.

[199]  Henrik Zetterberg,et al.  Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. , 2016, JAMA neurology.

[200]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[201]  Keith A. Johnson,et al.  Flortaucipir tau PET imaging in semantic variant primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[202]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[203]  R. Hubbard,et al.  Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples , 2017, Neurobiology of Aging.

[204]  Paul Edison,et al.  Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease , 2017, Brain : a journal of neurology.

[205]  M. Frosch,et al.  [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging , 2017, Acta Neuropathologica.

[206]  Keith A. Johnson,et al.  Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease , 2017, JAMA neurology.

[207]  M. Mintun,et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.

[208]  Hanna Cho,et al.  Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease , 2017, Neurobiology of Aging.

[209]  D. Perani.  Faculty Opinions recommendation of PET imaging of tau deposition in the aging human brain. , 2017 .

[210]  Luca Passamonti,et al.  Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses , 2017, BMJ Open.

[211]  D. Melzer,et al.  Small molecule modulation of splicing factor expression is associated with rescue from cellular senescence , 2017, BMC Cell Biology.

[212]  Keith A. Johnson,et al.  Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β , 2017, Alzheimer's & Dementia.

[213]  William J. Jagust,et al.  Tau and β-Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging , 2017, The Journal of Neuroscience.

[214]  Keith A. Johnson,et al.  Cued memory decline in biomarker-defined preclinical Alzheimer disease , 2017, Neurology.

[215]  C. Jack,et al.  Age and sex specific prevalences of cerebral β-amyloidosis, tauopathy and neurodegeneration among clinically normal individuals aged 50-95 years: a cross-sectional study , 2017, The Lancet Neurology.

[216]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[217]  Christopher C Rowe,et al.  Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET , 2017, Brain : a journal of neurology.

[218]  David T. Jones,et al.  Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals , 2017, JAMA neurology.

[219]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[220]  James G. Bollinger,et al.  Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.

[221]  Henrik Zetterberg,et al.  18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease , 2017, EMBO molecular medicine.

[222]  Sang Won Seo,et al.  Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort , 2016, NeuroImage: Clinical.

[223]  Alzheimer's Disease Neuroimaging Initiative.  Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .

[224]  Keith A. Johnson,et al.  Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies , 2017, Annals of neurology.

[225]  K. Blennow,et al.  CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[226]  Eric E. Smith,et al.  Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer's disease , 2017, Alzheimer's & Dementia.

[227]  Rik Ossenkoppele,et al.  Distinct 18F‐AV‐1451 tau PET retention patterns in early‐ and late‐onset Alzheimer's disease , 2017, Brain : a journal of neurology.

[228]  William J. Jagust,et al.  Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease , 2017, NeuroImage.

[229]  F. Schmitt,et al.  Challenges and Considerations Related to Studying Dementia in Blacks/African Americans. , 2017, Journal of Alzheimer's disease : JAD.

[230]  J. Phillips,et al.  Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease , 2018, Human brain mapping.

[231]  J. Phillips,et al.  18F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease , 2017, The Journal of Nuclear Medicine.

[232]  M. Mintun,et al.  Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity , 2017, The Journal of Nuclear Medicine.

[233]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[234]  Ron Brookmeyer,et al.  Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States , 2018, Alzheimer's & Dementia.

[235]  F. Turkheimer,et al.  Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[236]  J. Tribble,et al.  Early Alzheimer’s Disease: Developing Drugs for Treatment (FDA Draft Guidance for Industry) , 2019 .